Trials / Completed
CompletedNCT03842163
Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology
PREVALENCE AND CHARACTERISTICS OF TRANSTHYRETIN AMYLOIDOSIS IN PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY OF UNKNOWN ETIOLOGY TTRACK
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 812 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 50 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to determine the prevalence of ATTR Cardiomyopathy among patients admitted due to Left Ventricular Hypertrophy (LVH) \>15mm of unknown etiology by using a 99mTc-tracer scintigraphy based protocol
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Diagnosis of TTR amyloidosis cardiomyopathy | Diagnosis of TTR amyloidosis cardiomyopathy with scintigraphy |
Timeline
- Start date
- 2018-07-09
- Primary completion
- 2022-06-08
- Completion
- 2022-06-08
- First posted
- 2019-02-15
- Last updated
- 2024-02-12
- Results posted
- 2024-02-12
Locations
18 sites across 10 countries: Australia, Austria, France, Italy, Portugal, Romania, Slovakia, Slovenia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT03842163. Inclusion in this directory is not an endorsement.